If the purpose of the bankruptcy auction was to maximize the value of what was left of the Amyris consumer brand portfolio, it's difficult to see how that objective was achieved when the crown jewel of the portfolio was auctioned off for less then the stock and receivables. Factors that may have attibuted to the rock-bottom prices are the fact that none of Amyris’ consumer brands are profitable, and in the case of Rose Inc, JVN Hair, and 4U By Tia, the value of the company is encumbered by the continued involvement of the celebrity collaborator.Amyris Chief Financial Officer Han Kieftenbeld—the interim Chief Executive Officer since CEO and President John Melo resigned after 16 years at the company in June—laid the blame for the company's financial strains on several factors including the fact that Amyris has always operated at a loss, requiring a constant stream of equity and debt financing to continue operations. Amyris began in 2003 with a $42 million grant from the Bill and Melinda Gates Foundation to create a molecule to treat malaria and went on to raise $1.9 billion over 26 rounds including a post-IPO Equity Round.Amyris' total revenues have plummeted by more than 20% over the past two years, posting $341.8 million in revenue in 2021 and dropping to $269.8 million in 2022. The net sales of the consumer brands fell from $175.5 million in 2022 to $59 million as of June 2023, with Biossance making up 48% of the revenue.